Surmodics, Inc.: 6-Month Data from the Surmodics SWING BTK First-in-Human Trial Presented at AMP Europe
Sundance Sirolimus DCB demonstrates lowest binary restenosis at 6 months compared to relevant BTK clinical trials Excellent safety profile observed with no major amputations and low rates of MAE Surmodics
Source: finanznachrichten.de